Literature DB >> 1154282

Comparative distribution and embryotoxicity of hydroxyurea in pregnant rats and rhesus monkeys.

J G Wilson, W J Scott, E J Ritter, R Fradkin.   

Abstract

Hydroxyurea was given to pregnant rhesus monkeys and pregnant rats in regimens adjusted to produce similar degrees of teratogenicity, for the purpose of comparing the distribution of the drug in the females and their embryos. According, in rats 137 mg/kg/day ip on days 9-12 resulted in a drug half-life in maternal plasma of about 15 min and in embryos about 85 min, after the last injection; and in monkeys 100 mg/kg/days iv on days 23-32 resulted in drug half-life in maternal plasma estimated to be 120 min and in embryos 265 min, after the last injection. Using as a baseline of biological effects the minimal concentration known to inhibit DNA synthesis in rat embryos and cancer cells, namely 10(-4) M, it was calculated that the rat embryos in the present study were exposed to this level or more for approximately 12 h whereas the monkey embryos were exposed for approximately 100 h. Although the teratogenic effects were not identical in the two species, these data are interpreted to mean that rat embryos are teratogenically much more sensitive to hydroxyurea than monkey embryos. These observations have important implications in the selection of appropriate species for tests to estimate human teratogenic risks. The rat, which is currently the most widely used animal for such tests, displays sizeable differences from rhesue monkeys, which is one of the animals thought to be most like man in teratogenic susceptibility.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1154282     DOI: 10.1002/tera.1420110205

Source DB:  PubMed          Journal:  Teratology        ISSN: 0040-3709


  11 in total

Review 1.  Pharmacokinetics and pharmacodynamics of hydroxyurea.

Authors:  P R Gwilt; W G Tracewell
Journal:  Clin Pharmacokinet       Date:  1998-05       Impact factor: 6.447

2.  Pregnancy outcomes with hydroxyurea use in women with sickle cell disease.

Authors:  Barbara L Kroner; Jane S Hankins; Norma Pugh; Abdullah Kutlar; Allison A King; Nirmish R Shah; Julie Kanter; Jeffrey Glassberg; Marsha Treadwell; Victor R Gordeuk
Journal:  Am J Hematol       Date:  2022-02-17       Impact factor: 10.047

3.  Unraveling the Mechanisms of Clinical Drugs-Induced Neural Tube Defects Based on Network Pharmacology and Molecular Docking Analysis.

Authors:  Zhen Guan; Yingchao Liang; Xiuwei Wang; Zhiqiang Zhu; Aiyun Yang; Shen Li; Jialu Yu; Bo Niu; Jianhua Wang
Journal:  Neurochem Res       Date:  2022-08-12       Impact factor: 4.414

4.  Effects of hydroxyurea on postnatal growth and behaviour of rats.

Authors:  H Fritz; R Hess
Journal:  Agents Actions       Date:  1980-09

5.  Evaluation and treatment of the human immunodeficiency virus-1-exposed infant.

Authors: 
Journal:  Paediatr Child Health       Date:  2004-07       Impact factor: 2.253

Review 6.  Hydroxyurea in the treatment of HIV infection: clinical efficacy and safety concerns.

Authors:  Julianna Lisziewicz; Andrea Foli; Mark Wainberg; Franco Lori
Journal:  Drug Saf       Date:  2003       Impact factor: 5.606

7.  Species differences in pharmacokinetics and drug teratogenesis.

Authors:  H Nau
Journal:  Environ Health Perspect       Date:  1986-12       Impact factor: 9.031

8.  Interagency regulatory liaison group workshop on reproductive toxicity risk assessment.

Authors:  C A Kimmel; G L Kimmel; V Frankos
Journal:  Environ Health Perspect       Date:  1986-04       Impact factor: 9.031

9.  Shoutai pills improve the quality of oocytes exposed to the chemotherapeutic drug Hydroxyurea.

Authors:  Yuwei Zhang; Ruizhi Tan; Li Wang; Xiaoyan Shi; Yu Li; Xia Zhong; Xiaoxia He; Bo Xiong
Journal:  Aging (Albany NY)       Date:  2020-05-10       Impact factor: 5.682

10.  Tolerability and age-dependent toxicokinetics following perinatal hydroxyurea treatment in Sprague Dawley rats.

Authors:  Madelyn C Huang; Katie J Turner; Molly Vallant; Veronica G Robinson; Yi Lu; Catherine J Price; Timothy R Fennell; Melanie A Silinski; Suramya Waidyanatha; Kristen R Ryan; Sherry R Black; Reshan A Fernando; Barry S McIntyre
Journal:  J Appl Toxicol       Date:  2020-11-25       Impact factor: 3.628

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.